| Literature DB >> 31267722 |
Eleonora Bardi1, Joanna Majerczak2,3, Jerzy A Zoladz2, Urszula Tyrankiewicz4, Tomasz Skorka5, Stefan Chlopicki4,6, Magdalena Jablonska5, Anna Bar4, Krzysztof Jasinski5, Alessia Buso7, Desy Salvadego7, Zenon Nieckarz2, Bruno Grassi7,8, Roberto Bottinelli1,9,10, Maria Antonietta Pellegrino1,10,11.
Abstract
Physical activity is emerging as an alternative nonpharmaceutical strategy to prevent and treat a variety of cardiovascular diseases due to its cardiac and skeletal muscle beneficial effects. Oxidative stress occurs in skeletal muscle of chronic heart failure (CHF) patients with possible impact on muscle function decline. We determined the effect of voluntary-free wheel running (VFWR) in preventing protein damage in Tgαq*44 transgenic mice (Tg) characterized by a delayed CHF progression. In the early (6 months) and transition (12 months) phase of CHF, VFWR increased the daily mean distance covered by Tg mice eliminating the difference between Tg and WT present before exercise at 12 months of age (WT Pre-EX 3.62 ± 1.66 vs. Tg Pre-EX 1.51 ± 1.09 km, P < 0.005; WT Post-EX 5.72 ± 3.42 vs. Tg Post-EX 4.17 ± 1.8 km, P > 0.005). This effect was concomitant with an improvement of in vivo cardiac performance [(Cardiac Index (mL/min/cm2 ): 6 months, untrained-Tg 0.167 ± 0.005 vs. trained-Tg 0.21 ± 0.003, P < 0.005; 12 months, untrained-Tg 0.1 ± 0.009 vs. trained-Tg 0.133 ± 0.005, P < 0.005]. Such effects were associated with a skeletal muscle antioxidant response effective in preventing oxidative damage induced by CHF at the transition phase (untrained-Tg 0.438 ± 0.25 vs. trained-Tg 0.114 ± 0.010, P < 0.05) and with an increased expression of protein control markers (MuRF-1, untrained-Tg 1.12 ± 0.29 vs. trained-Tg 14.14 ± 3.04, P < 0.0001; Atrogin-1, untrained-Tg 0.9 ± 0.38 vs. trained-Tg 7.79 ± 2.03, P < 0.01; Cathepsin L, untrained-Tg 0.91 ± 0.27 vs. trained-Tg 2.14 ± 0.55, P < 0.01). At the end-stage of CHF (14 months), trained-Tg mice showed a worsening of physical performance (decrease in daily activity and weekly distance and time of activity) compared to trained age-matched WT in association with oxidative protein damage of a similar level to that of untrained-Tg mice (untrained-Tg 0.62 ± 0.24 vs. trained-Tg 0.64 ± 0.13, P > 0.05). Prolonged voluntary physical activity performed before the onset of CHF end-stage, appears to be a useful tool to increase cardiac function and to reduce skeletal muscle oxidative damage counteracting physical activity decline.Entities:
Keywords: Chronic heart failure; oxidative stress; voluntary physical activity
Mesh:
Substances:
Year: 2019 PMID: 31267722 PMCID: PMC6606516 DOI: 10.14814/phy2.14161
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Cardiac performance in Tgαq*44 mice before and after 2 months of spontaneous activity
| Tg‐6mo | Tg‐12mo | Tg‐14mo | ||||
|---|---|---|---|---|---|---|
| Tg‐CTRL ( | Tg‐T ( | Tg‐CTRL ( | Tg‐T ( | Tg‐CTRL ( | Tg‐T ( | |
| Body mass | 25.8 ± 0.5 | 24.9 ± 0.5 | 29.5 ± 3.0 | 28.6 ± 1.3 | 29.2 ± 0.7 | 28.5 ± 0.4 |
| CI [mL/min/cm2] | 0.167 ± 0.005 | 0.21 ± 0.003 | 0.101 ± 0.009 | 0.133 ± 0.005 | 0.116 ± 0.005 | 0.119 ± 0.005 |
| HR [bpm] | 491 ± 9 | 499 ± 3 | 348 ± 14 | 361 ± 9 | 321 ± 7 | 321 ± 6 |
| ESV [μL] | 20.0 ± 0.9 | 25.0 ± 1.3 | 31.9 ± 3.2 | 29.9 ± 1.3 | 32.5 ± 3.5 | 30.1 ± 3.8 |
| EDV [μL] | 49.2 ± 1.1 | 60.3 ± 1.6 | 59.3 ± 3.4 | 63.7 ± 2.0 | 65.1 ± 4.7 | 62.6 ± 4.4 |
| SV [μL] | 29.2 ± 0.7 | 35.2 ± 0.7 | 27.4 ± 2.4 | 33.7 ± 1.1 | 32.6 ± 2.0 | 32.5 ± 1.1 |
| EF [%] | 59.5 ± 1.4 | 58.7 ± 1.4 | 46.5 ± 4.4 | 53.0 ± 1.1 | 51.5 ± 2.9 | 53.6 ± 3.2 |
| ER [SV/RR] | 2.91 ± 0.13 | 3.15 ± 0.10 | 3.65 ± 0.38 | 4.03 ± 0.24 | 4.02 ± 0.18 | 3.99 ± 0.10 |
| FR [SV/RR] | 4.01 ± 0.15 | 3.75 ± 0.10 | 5.11 ± 0.42 | 5.71 ± 0.62 | 5.61 ± 0.46 | 5.29 ± 0.32 |
| ET [%RR] | 39.5 ± 1.4 | 32.3 ± 1.0 | 30.0 ± 2.2 | 27.0 ± 1.8 | 27.4 ± 1.4 | 25.9 ± 0.9 |
| IVRT [%RR] | 13.0 ± 0.7 | 14.7 ± 0.8 | 9.2 ± 2.3 | 11.9 ± 0.9 | 11.2 ± 0.9 | 10.5 ± 0.6 |
| FT [%] | 34.5 ± 1.8 | 37.7 ± 1.2 | 28.1 ± 4.0 | 27.5 ± 1.9 | 25.2 ± 2.4 | 25.8 ± 2.9 |
| IVCT [% RR] | 12.9 ± 0.6 | 15.2 ± 0.7 | 32.7 ± 5.0 | 33.5 ± 2.4 | 36.1 ± 2.9 | 37.6 ± 2.7 |
| LA EF [%] | 0.16 ± 0.03 | 0.23 ± 0.01 | 0.10 ± 0.04 | 0.14 ± 0.02 | 0.05 ± 0.01 | 0.06 ± 0.01 |
CI, Cardiac Index; CHF, chronic heart failure; HR, Heart Rate; ESV, End Systolic Volume; EDV, End Diastolic Volume; SV, Stroke Volume; EF, Ejection Fraction; ER, Ejection Rate; FR, Filling Rate (ER and FR were normalized to individual SV and R‐R values); ET, Ejection Time; IVRT, Isovolumic Relaxation Time; FT, Filling Time; IVCT, Isovolumic Contraction Time; LAEF, Left Atrial Ejection Fraction.
Cardiac parameters of transgenic mice at different stages of CHF;
Significantly different from untrained Tg mice (Tg‐CTRL) at given age (P < 0.05, t‐test);
Significantly different between transgenic mice (Tg‐CTRL) at a given age as compared to 6 months old Tg‐CTRL mice (P < 0.05; One‐way ANOVA); No differences were detected between Tg‐CTRL at the age of 12 and 14 months of age.
Figure 1In vivo functional performance. Delta of variation of (A) weekly distance of running (km) and (B) weekly time of running (h) between wild‐type (WT) and transgenic (Tg) trained mice. Star marks show significant difference between Tg‐T and age‐matched WT‐T ***P < 0.001. ♦significant different from Tg‐T 6‐mo and 12‐mo P < 0.05; (C) daily mean distance (km) covered by WT and Tg mice before (Pre‐EX) and after (Post‐EX) 2 months of voluntary wheel running at different stages of heart failure. Data are shown as mean ± SD. Star marks show significant difference between Pre‐EX and Post‐EX *P < 0.05 ***P < 0.001. ●significant different from WT Post‐EX 14 months P < 0.05. # significant different from WT Pre‐EX 12 months P < 0.05.
Figure 2MHC isoforms composition. Myosin heavy chain (MHC) isoforms composition in WT‐CTRL, Tg‐CTRL, and Tg‐T groups, at 6, 12, and 14 months of age that correspond to different stages of heart failure. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 3Antioxidant defense system. Quantification of (A) SOD1(superoxide dismutase 1) protein level and (B) catalase protein level by western blot analysis (C) proteins carbonylation by Oxyblot analysis in WT‐CTRL, Tg‐CTRL, and Tg‐T mice, at 6, 12, and 14 months of age that correspond to different stages of heart failure. Data are shown as mean ± SD *P < 0.05 **P < 0.01 ***P < 0.001.
Figure 4Protein quality control systems. Quantification of mRNA levels of (A) Atrogin‐1, (B) MuRF‐1 (muscle‐specific ring finger protein‐1) and (D) cathepsin L by RT‐PCR (C) protein level quantification of LC3 (microtubule‐associated protein light chain 3) based on the ratio between the content in forms II and I of LC3 by western blotting in WT‐CTRL, Tg‐CTRL, and Tg‐T mice, at 6, 12, and 14 months of age that correspond to different stages of heart failure. Data are shown as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 5Energetic and oxidative parameters. Quantification of (A) AMPK (AMP‐activated protein kinase) phosphorylation level (B) PGC‐1α (peroxisome proliferative activated receptor‐γ coactivator 1α) protein level (C) DRP1 (dynamin‐related protein 1) protein level (D) Mfn‐1 (mitofusin1) protein level (E) mitochondrial complexes protein levels (I, II, III, IV, V) by western blot analysis in WT‐CTRL, Tg‐CTRL and Tg‐T mice, at 6, 12 and 14 months of age that correspond to different stages of heart failure. The activity level of AMPK was calculated as the ratio between the content in the phosphorylated (p‐form) and total form. Data are shown as mean ± SD. *P < 0.05 **P < 0.01 ***P < 0.001 ****P < 0.0001.